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Introduction {#onco13368-sec-0006}
============

Colorectal cancers with microsatellite instability (MSI‐H) are associated with high mutation load, increased tumor infiltrating lymphocytes, and high expression of checkpoints such as programmed cell death protein 1 (PD‐1), cytotoxic T‐lymphocyte‐associated protein 4 and lymphocyte‐activation gene 3 [1](#onco13368-bib-0001){ref-type="ref"}. Microsatellite stable (MSS) colorectal cancers are considerably less mutated and are characterized by a less inflamed tumor immune microenvironment [1](#onco13368-bib-0001){ref-type="ref"}. Although the targeting of PD‐1 has been associated with robust clinical responses in colorectal cancer with MSI‐H, limited antitumor activity was observed in MSS colorectal cancers even after selecting for programmed death‐ligand 1 (PD‐L1) expression [2](#onco13368-bib-0002){ref-type="ref"}, [3](#onco13368-bib-0003){ref-type="ref"}.

Regorafenib is a small molecule tyrosine kinase inhibitor with inhibitory activity against multiple targets involved in tumor angiogenesis and oncogenesis. Preclinical studies have demonstrated the enhanced concomitant antitumor activity of regorafenib and anti--PD‐1 in in vivo colorectal cancer models [4](#onco13368-bib-0004){ref-type="ref"}. Mechanistically, this effect may be mediated by (a) a reduction of tumor‐associated macrophages (TAMs), (b) reprogramming of TAMs toward an M1 phenotype by the inhibition of colony‐stimulating factor 1 receptor by regorafenib [4](#onco13368-bib-0004){ref-type="ref"}, (c) suppression of interferon gamma--induced PD‐L1 and indoleamine 2, 3‐dioxygenase 1 expression [5](#onco13368-bib-0005){ref-type="ref"}, and (d) inhibition of vascular endothelial growth factor receptor and its signaling pathway, which may normalize tumor blood vessels and thereby improve cytotoxic T cell infiltration [6](#onco13368-bib-0006){ref-type="ref"}. A recent study of regorafenib and nivolumab reported a 33% response rates and a median progression‐free survival of more than 6 months in a cohort of 24 Japanese patients with MSS chemoresistant metastatic colorectal cancers [7](#onco13368-bib-0007){ref-type="ref"}. These findings were met with hope and excitement within the medical oncology community in the U.S., with many centers considering the combination of regorafenib and PD‐1 inhibitors on compassionate basis for refractory MSS colorectal cancers.

Here, we report on our experience with the compassionate administration of regorafenib plus PD‐1 inhibitors in patients with advanced, refractory, MSS colorectal cancers.

Subjects, Materials, and Methods {#onco13368-sec-0007}
================================

We performed a retrospective review of all patients with MSS colorectal cancer treated at a City of Hope Comprehensive Cancer Center who received a PD‐1 inhibitor in combination with regorafenib on a compassionate basis. Eligibility for inclusion included the receipt of the combination of regorafenib plus nivolumab or the combination of regorafenib plus pembrolizumab in the setting of MSS colorectal cancer and following disease progression on standard of care therapy, which included fluorouracil, oxaliplatin, and irinotecan. Because the intent of the combination was synergistic, patients with prior exposure to regorafenib monotherapy or to an anti--PD‐1 monotherapy prior to receipt of the combination were also included. Responses were assessed by the study investigator using RECIST 1.1 guidelines. Progression‐free survival was measured from start of treatment to time of progression. The study was conducted under an institutional review board--approved protocol, IRB14361.

Treatment {#onco13368-sec-0008}
---------

Patients received regorafenib at 80 mg p.o. once a day for 21 days every 28‐day cycle. Patient receiving regorafenib plus nivolumab received nivolumab at 240 mg intravenously every 2 weeks starting day 1 of regorafenib. Patients receiving regorafenib plus pembrolizumab received pembrolizumab at 200 mg intravenously every 3 weeks.

Circulating Tumor DNA Assay {#onco13368-sec-0009}
---------------------------

When feasible, patients underwent Guardant360 circulating tumor DNA (ctDNA) assay (Guardant Health, Inc, Redwood City, CA) before initiation of treatment and after cycle 1 of treatment. Guardant360 sequencing technique is based on a next‐generation sequencing technology (Guardant Digital Sequencing) with a single‐molecule analytical sensitivity and a 99.9999% specificity [8](#onco13368-bib-0008){ref-type="ref"}.

Results {#onco13368-sec-0010}
=======

Patient Characteristics {#onco13368-sec-0011}
-----------------------

A total of 18 patients with MSS colorectal cancer (16 men, 88.9%) were treated with a combination of regorafenib and PD‐1 inhibitors and were evaluable for response. Baseline characteristics are listed in Table [1](#onco13368-tbl-0001){ref-type="table"}. All patients had progressed on all prior standard therapies. A total of 17 patients received regorafenib plus nivolumab, and 1 patient received regorafenib plus pembrolizumab. Twelve patients (66.7%) had left‐sided primary tumor, and six patients (33.3%) had right‐sided primary tumor. Liver metastases were recorded in 14 (77.8%) patients (Table [2](#onco13368-tbl-0002){ref-type="table"}). For the four (22.2%) patients without a history of liver metastases, three patients were with lung metastases, and one patient was with pelvic metastases. Six patients had prior anti--PD‐1/PD‐L1 on clinical trials but no concurrent regorafenib exposure. Two patient had prior regorafenib exposure (2 months, with progressive disease \[PD\]) but without concurrent anti--PD‐1/PD‐L1 exposure. Tumor mutation burden (TMB) was available in 15 patients, with low TMB observed among all patients.

###### 

Patients characteristics

  Age, yr   Sex   Race    Primary tumor location   Prior liver metastasis resection   Sites of metastases when on treatment   Prior PD‐1/PD‐L1 inhibitor   Duration and response on prior PD‐1/PD‐L1 inhibitor, mo   ECOG PS   Regimen       TMB (mutations per Mb)   No. of Cycles   Response
  --------- ----- ------- ------------------------ ---------------------------------- --------------------------------------- ---------------------------- --------------------------------------------------------- --------- ------------- ------------------------ --------------- ----------
  55        M     White   Left                     Yes                                Lung                                    Yes                          PD (2)                                                    0         Rego + nivo   3                        2               PD
  75        M     White   Right                    Yes                                Lung                                    No                                                                                     0         Rego + nivo   3                        2               PD
  53        M     White   Left                     No                                 Lung, peritoneum                        Yes                          SD (16)                                                   1         Rego + nivo   2                        8               SD
  67        M     Asian   Left                     No                                 Lung                                    Yes                          SD (8)                                                    1         Rego + pem    4                        9               SD
  52        M     White   Right                    No                                 Liver, lymph node                       No                                                                                     1         Rego + nivo   7                        2               PD
  73        M     Asian   Right                    Yes                                Lung                                    No                                                                                     1         Rego + nivo   11                       2               PD
  65        M     White   Left                     Yes                                Liver, peritoneal, spleen, RPLN         No                                                                                     1         Rego + nivo   4                        2               PD
  65        M     White   Right                    No                                 Liver, lung, lymph node                 Yes                          PD (1)                                                    1         Rego + nivo   NA                       2               PD
  60        M     NA      Left                     No                                 Lung, RPLN                              No                                                                                     1         Rego + nivo   5                        7               SD
  57        M     NA      Left                     Yes                                Lung                                    No                                                                                     0         Rego + nivo   7                        4               SD
  75        M     Asian   Left                     Yes                                Liver, lung, bone                       No                                                                                     1         Rego + nivo   6                        2               PD
  43        M     Asian   Left                     Yes                                Liver, lung, peritoneum, lymph node     Yes                          PD (1)                                                    1         Rego + nivo   NA                       4               PD
  48        M     White   Left                     Yes                                Liver, lung                             No                                                                                     1         Rego + nivo   6                        3               PD
  67        F     White   Left                     Yes                                Lung, RPLN, hilar adenopathy, brain     No                                                                                     0         Rego + nivo   NA                       2               PD
  54        M     Asian   Left                     Yes                                Liver, lung, RPLN                       No                                                                                     1         Rego + nivo   2                        2               PD
  60        M     White   Right                    Yes                                Lung                                    Yes                          SD (5)                                                    1         Rego + nivo   2                        1               PD
  47        M     White   Left                     No                                 Pelvic                                  No                                                                                     0         Rego + nivo   4                        4               SD
  79        F     White   Right                    No                                 Liver, lymph nodes                      No                                                                                     1         Rego + nivo   6                        1               PD

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; F, female; M, male; NA, not available; Nivo, nivolumab; PD, progressive disease; PD‐1, programmed cell death protein 1; PD‐L1, programmed death‐ligand 1; Pem, pembrolizumab; Rego, regorafenib; RPLN, retroperitoneal lymph node; SD, stable disease; TMB, tumor mutation burden.

###### 

Patient characteristics summary

  Characteristics           Total (*n* = 18), *n* %
  ------------------------- -------------------------
  Median age, (range), yr   60 (43--79)
  ECOG PS                   
  0                         5 (27.8)
  1                         13 (72.2)
  Sex                       
  Male                      16 (88.9)
  Female                    2 (11.1)
  Primary tumor location    
  Left                      12 (66.7)
  Right                     6 (33.3)
  Liver metastases          
  Yes                       14 (77.8)
  No                        4 (22.2)
  Prior anti‐PD‐1/PD‐L1     6 (38)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; PD‐1, programmed cell death protein 1; PD‐L1, programmed death‐ligand 1.

Safety {#onco13368-sec-0012}
------

Treatment administration was well tolerated, with no significant toxicities being recorded while on treatment. Hematological toxicities were limited to grade 1 toxicities. Skin toxicities were limited to grade 1 except for one patient who developed a grade 2 immune related dermatitis that responded well to topical steroids (Table [3](#onco13368-tbl-0003){ref-type="table"}). No patient required dose reductions or interruptions. No grade 3 or above toxicities were noted on treatment.

###### 

On‐study adverse events (*n* = 18)

  Adverse event         All cycles                                 
  --------------------- ------------ --------- --------- --------- ---------
  Anemia                1 (5.5)      0 (0.0)   0 (0.0)   0 (0.0)   0 (0.0)
  WBC decrease          0 (0.0)      0 (0.0)   0 (0.0)   0 (0.0)   0 (0.0)
  Neutrophil decrease   0 (0.0)      0 (0.0)   0 (0.0)   0 (0.0)   0 (0.0)
  Platelet decrease     2 (11.1)     0 (0.0)   0 (0.0)   0 (0.0)   0 (0.0)
  AST increase          0 (0.0)      0 (0.0)   0 (0.0)   0 (0.0)   0 (0.0)
  ALT increase          0 (0.0)      0 (0.0)   0 (0.0)   0 (0.0)   0 (0.0)
  ALP increase          1 (5.5)      0 (0.0)   0 (0.0)   0 (0.0)   0 (0.0)
  Skin rash             1 (5.5)      1 (5.5)   0 (0.0)   0 (0.0)   0 (0.0)

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; WBC, white blood cell.

Efficacy {#onco13368-sec-0013}
--------

All patients were evaluable for treatment response assessment. Per investigator review, which concurred with the official radiology reviews, no objective responses were noted on treatment. Thirteen patients (72.2%) had progressive disease, and five patients (27.8%) experienced stable disease. (Table [1](#onco13368-tbl-0001){ref-type="table"}). Six patients included on this study had prior PD‐1/PD‐L1 therapy. Two of the three patients who had stable disease as a best response on prior immunotherapy experienced stable disease, whereas all three patients who had progressive disease as best response on prior immunotherapy had disease progression. Neither of the two patients who had received prior regorafenib exhibited a response. Median progression‐free survival was 2 months (Fig. [1](#onco13368-fig-0001){ref-type="fig"}A). The duration of stable disease (SD) was 8+ months in one patient treated with pembrolizumab plus regorafenib (with prior pembrolizumab exposure), 7 months in one patient with prior atezolizumab exposure, 8+ months in one patient, 4 months in one patient, and 4+ months in one patient (Table [4](#onco13368-tbl-0004){ref-type="table"}). Notably, four out of five patients with SD had no history of liver metastases, and all 13 patients who had PD had history of liver metastases (Tables [1](#onco13368-tbl-0001){ref-type="table"}, [4](#onco13368-tbl-0004){ref-type="table"}). Three of the patients with SD were encountered in checkpoint‐inhibitor naive patients, whereas two patients with SD (8+ months and 8 months) were seen among the six patients with prior PD‐1 or PD‐L1 exposures (Table [1](#onco13368-tbl-0001){ref-type="table"}). Overall survival analysis remains immature, as the median follow‐up is only 7 months (Fig. [1](#onco13368-fig-0001){ref-type="fig"}B).

![Progression‐free survival and overall survival. **(A):** Progression‐free survival. **(B):** Overall survival.](ONCO-25-e1188-g001){#onco13368-fig-0001}

###### 

Metastatic pattern and duration of benefit in patients with SD

  Patient   Metastatic site when on treatment   Prior liver metastases   Duration of SD, mo
  --------- ----------------------------------- ------------------------ --------------------
  1         Lung, peritoneum                    no                       7
  2         Lung                                no                       8+
  3         Lung, RPLN                          no                       8+
  4         Lung                                yes                      4
  5         Pelvic                              no                       4+

Abbreviations: RPLN, retroperitoneal lymph node; SD, stable disease.

ctDNA and Carcinoembryonic Antigen Monitoring {#onco13368-sec-0014}
---------------------------------------------

ctDNA assays were evaluated at baseline and at 4 weeks of treatment in 13 patients (Fig. [2](#onco13368-fig-0002){ref-type="fig"}A--D). All 10 patients with a rise in ctDNA or emergence of new clones at 4 weeks had PD at the 2‐month imaging point (Fig. [2](#onco13368-fig-0002){ref-type="fig"}E). Three patients with declining ctDNA at 4 weeks experienced SD for 8+ months, 7 month, and 4+ months each (Fig. [2](#onco13368-fig-0002){ref-type="fig"}F). To investigate the correlation of ctDNA and carcinoembryonic antigen (CEA) in monitoring tumor response, we analyzed 10 PD and 3 SD patients with paired CEA and ctDNA. The dynamics of CEA were shown at baseline, 4 weeks, and 8 weeks after treatment. For 10 patients with PD, 4 patients had a CEA decline at 4 weeks, and 6 patients had a CEA increase at 4 weeks (Fig. [3](#onco13368-fig-0003){ref-type="fig"}A). For three patients with SD, two patients had a CEA surge at 4 weeks, followed by a decline (Fig. [3](#onco13368-fig-0003){ref-type="fig"}B). ctDNA at 4 weeks was more accurate in predicting a radiographic benefit than CEA.

![Guradant360 ctDNA assay of patients treated with regorafenib and PD‐1 inhibitor. **(A, B):** ctDNA of SD patients. **(C, D):** ctDNA of PD patients. **(E):** The highest MAF change at baseline and 4 weeks after treatment in patients with PD. **(F):** The highest MAF change at baseline and 4 weeks after treatment in patients with SD.\
Abbreviations: MAF, mutation allele frequency; PD, progressive disease; SD, stable disease.](ONCO-25-e1188-g002){#onco13368-fig-0002}

![CEA response of patients treated with regorafenib and PD‐1 inhibitor. **(A):** CEA changes in patients with progressive disease. **(B):** CEA changes in patients with stable disease.\
Abbreviations: CEA, carcinoembryonic antigen; PD, progressive disease; SD, stable disease.](ONCO-25-e1188-g003){#onco13368-fig-0003}

Discussion {#onco13368-sec-0015}
==========

Tumors with microsatellite instability have been associated with robust responses to PD‐1 inhibitors [9](#onco13368-bib-0009){ref-type="ref"}, [10](#onco13368-bib-0010){ref-type="ref"}, [11](#onco13368-bib-0011){ref-type="ref"}, [12](#onco13368-bib-0012){ref-type="ref"}. Microsatellite stable tumors, known for low tumor mutational burden and lack of significant immune cell infiltration, remain resistant to immunotherapy [1](#onco13368-bib-0001){ref-type="ref"}, [2](#onco13368-bib-0002){ref-type="ref"}. Numerous investigations are underway to explore the potential of combination immunotherapies to convert MSS colorectal cancer to an immune‐responsive malignancy. Preclinical studies have demonstrated synergy between regorafenib and PD‐1 inhibitors in colorectal cancer models [4](#onco13368-bib-0004){ref-type="ref"}. In addition, a recent Japanese trial, the REGONIVO study, reported a robust response rate in Japanese patients with MSS metastatic colorectal cancer [7](#onco13368-bib-0007){ref-type="ref"}. In our study, we did not observe any responses in our patients treated with this regimen. Stable disease was recorded in five (31%) patients, four of which occurred in patients without any existing or history of liver metastases. Progressive disease was observed in 13 (69%) patients, all of whom with existing or history of liver metastases. Interestingly, all clinical benefits occurred in patients with left‐sided tumors. However, all six patients with right‐sided tumors had history of liver metastases prior to or at the time of treatment with regorafenib and nivolumab. Given this limitation, we cannot assess an independent impact of sidedness on treatment outcome. Clinical benefit was observed in patients with *RAS* mutant (3) and *RAS* wild‐type (2).

The pattern of metastatic disease may impact the responsiveness to PD‐1/PD‐L1 inhibitors. Prior clinical studies have shown that patients with melanoma and non‐small cell lung cancer (NSCLC) with liver metastasis have a diminished likelihood of response and a shortened survival when treated with PD‐1 inhibitors in comparison to patients with melanoma and NSCLC without liver metastases [13](#onco13368-bib-0013){ref-type="ref"}. Tumor biopsies from these studies revealed lower CD8+ T cell infiltration in the primary tumor of the liver metastasis group when compared with the non‐liver metastasis group. In addition, patients with liver metastases had lower CD8+ T cells in extrahepatic distant metastases, which suggest that patients with liver metastases suffer from a diminished antitumor immune response and may be less likely to benefit from checkpoint inhibition. It is also possible that liver metastases have a systemic immunosuppressive effect, which diminishes the immune response both intra and extrahepatically in patients with solid tumors. The fact that liver allografts are accepted without the need for histocompatibility suggests that liver can induce peripheral immune tolerance in immune‐competent recipients [14](#onco13368-bib-0014){ref-type="ref"}. In addition, liver transplantation makes liver recipients more tolerant to other organ transplantation from the same donor, suggesting that liver allografts can induce systemic immune suppression [15](#onco13368-bib-0015){ref-type="ref"}, [16](#onco13368-bib-0016){ref-type="ref"}. Mechanistically, this phenomenon could be explained by the deletion of activated CD8+ T cells [17](#onco13368-bib-0017){ref-type="ref"}, [18](#onco13368-bib-0018){ref-type="ref"}, poor CD8+ and CD4+ T cell activation [19](#onco13368-bib-0019){ref-type="ref"}, [20](#onco13368-bib-0020){ref-type="ref"}, and the activation of regulatory T cells by the liver [21](#onco13368-bib-0021){ref-type="ref"}. Therefore, we hypothesize that liver metastases take advantage of the liver immune tolerance that suppresses systemic antitumor immune response and renders PD‐1 inhibitors less effective.

Multiple mechanisms have been proposed to explain the immunomodulatory effect of regorafenib, including reduction of tumor infiltrating macrophages, enrichment in M1 macrophage phenotype, enhanced T cell activation, decreased regulatory T cell infiltration, and decreased inhibitory checkpoints expression such as indoleamine 2,3‐dioxygenase [4](#onco13368-bib-0004){ref-type="ref"}, [5](#onco13368-bib-0005){ref-type="ref"}, [7](#onco13368-bib-0007){ref-type="ref"}. Although no response was recorded in our cohort, the disease control in five patients, four without liver metastases, suggests its clinical activity when combined with nivolumab in a subset of MSS metastatic colorectal cancer. In addition, the protracted SD of 7 months or more in two patients with prior progression on pembrolizumab and atezolizumab provides preliminary evidence suggesting potential synergy between regorafenib and PD‐1 inhibitors. It also suggests that select patients who progressed on prior immunotherapy should not be necessarily excluded from consideration for the combination of regorafenib and PD‐1 blockade in a clinical trial setting.

In addition to investigating the efficacy of regorafenib and PD‐1 inhibitors, we evaluated the merits of ctDNA in predicting for radiographic response to this treatment combination. ctDNA has been suggested as a potential biomarker for monitoring and tailoring treatment in solid tumors. In patients with metastatic colorectal cancer receiving standard first‐line or second‐line chemotherapy, early reductions in ctDNA were correlated with radiological responses and disease outcome [22](#onco13368-bib-0022){ref-type="ref"}, [23](#onco13368-bib-0023){ref-type="ref"}. In the setting of immunotherapy, a reduction in ctDNA levels was associated with clinical response in patients with non‐small cell lung cancer, melanoma, and MSI‐H colorectal cancer treated with checkpoint blockade. Patients who experienced initial response followed by disease progression had an initial decline at the time of response followed by an increase in ctDNA levels at the time of progression [24](#onco13368-bib-0024){ref-type="ref"}, [25](#onco13368-bib-0025){ref-type="ref"}, [26](#onco13368-bib-0026){ref-type="ref"}. Here, we show that early ctDNA changes can predict for disease control in a small cohort of patients with MSS colorectal cancer treated with immunotherapy. Our paired CEA and ctDNA data analysis also suggest that ctDNA may be more accurate than CEA in monitoring early tumor response to immunotherapy. Given the expense associated with immunotherapy, and especially with the low potential of benefit in MSS colorectal cancers, the identification of an early biomarker of response is important to cut costs and decrease potential toxicities. Our findings will require further validation in a larger cohort of patients.

Our experience with regorafenib and nivolumab did not replicate the high response rate observed in the REGONIVO Japanese trial. We identify liver metastases as a predictive biomarker for lack of efficacy to this combination. It is possible that the discrepancy between our data and the Japanese study is related to differences in patient characteristics such as liver metastases. The REGONIVO trial has been presented at the American Society of Clinical Oncology but has not yet been published. The details of the demographics of that population have not been fully reported. Among 50 patients, equally divided among between colorectal and stomach cancer, 54% had liver metastases and 41% were PD‐L1 positive. These data were not detailed by site of disease (colorectal vs. gastric). It does appear that a lower proportion of liver metastases were noted on the REGONIVO trial. In addition, the percentage of PD‐L1 positivity is higher than would be expected [3](#onco13368-bib-0003){ref-type="ref"}. We have not evaluated PD‐L1 expression in our cohort. Finally, significant differences exist in terms of race between REGONIVO trial and ours, as all REGONIVO patients were Japanese. However, an impact of race on immune response has not been confirmed previously. We suggest caution from implementing the combination of regorafenib and nivolumab in clinical practice until additional supportive data from prospective trials emerge.
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